Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P08034
UPID:
CXB1_HUMAN
Alternative names:
Connexin-32; GAP junction 28 kDa liver protein
Alternative UPACC:
P08034; B2R8R2; D3DVV2; Q5U0S4
Background:
Gap junction beta-1 protein, also known as Connexin-32 and GAP junction 28 kDa liver protein, plays a pivotal role in cell communication. It forms connexons, facilitating the diffusion of materials of low molecular weight between neighboring cells, essential for maintaining tissue homeostasis.
Therapeutic significance:
The protein is implicated in Charcot-Marie-Tooth disease, X-linked dominant, 1, and Dejerine-Sottas syndrome, both peripheral nervous system disorders. Understanding the role of Gap junction beta-1 protein could open doors to potential therapeutic strategies for these debilitating conditions.